2026-04-25T13:22:00Z https://www.pub.unibl.org/oai

oai:pub.unibl.org:66639 2026-02-13T04:43:17Z

Saffety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study. /unibl/author/Amit Bar Or /unibl/author/Michal Dufek /unibl/author/Hrvoje Budincevic /unibl/author/Jelena Drulovic /unibl/author/Mario Habek /unibl/author/Le H Huan /unibl/author/Martin SVeber /unibl/author/Piia Thomas https://www.unibl.org/sr-lat/fis/zaposlen/3330-sanja-grgic /unibl/author/Spomenka Kidemet Piskac 2025-08 Academic Article text 666 656 /unibl/sci/idNaucniRad:37280 https://dx.doi.org/10.1016/S1474-4422(25)00174-7 THE LANCET NEUROLOGY 1474-4422 THE LANCET NEUROLOGY 1474-4422 A. Bar Or, M. Dufek, H. Budincevic, J. Drulovic, M. Habek, L. H Huan, M. SVeber, P. Thomas, FENopta study group S. Grgić, FENopta S. Kidemet Piskac, Saffety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study., THE LANCET NEUROLOGY, Vol. 24, No. 8, pp. 656 - 666, Aug, 2025 https://www.pub.unibl.org/s/cir/item/66639